Charité – Universitätsmedizin Berlin stands as one of Europe's largest and most prestigious university hospitals, with a history spanning over 300 years. Founded in 1710 as a small hospital attached to the Friedrich Wilhelm University, Charité has evolved into a global powerhouse of biomedical research and clinical care. The institution is renowned for its pioneering contributions to neurodegenerative disease research, combining basic science discoveries with cutting-edge clinical applications that have shaped the field worldwide[1].
The medical center encompasses multiple campuses across Berlin, including the famous Charité Mitte, Campus Benjamin Franklin, and Campus Virchow-Klinikum. With over 100 departments and institutes, Charité attracts researchers and clinicians from around the world, fostering an environment of interdisciplinary collaboration that is essential for tackling complex neurodegenerative disorders[2].
Charité's significance in neuroscience extends beyond Germany to the entire European continent. The institution hosts several major research consortia, including the German Center for Neurodegenerative Diseases (DZNE), the NeuroCure Excellence Cluster, and numerous European Union-funded collaborative projects. This research infrastructure enables translational research that bridges the gap between laboratory discoveries and clinical applications for patients with Alzheimer's disease, Parkinson's disease, and related disorders[3].
Charité's origins trace back to 1710 when King Frederick I of Prussia established a small hospital to serve the growing University of Berlin. The name "Charité" (meaning "charity" in French) reflected the institution's humanitarian mission. Throughout the 19th and 20th centuries, Charité grew steadily, becoming one of the most important medical institutions in Europe despite the upheavals of two world wars and the division of Berlin.
The post-war period saw remarkable reconstruction and expansion, with Charité reuniting its campuses after German reunification in 1990. Today, the institution employs over 17,000 people, including 4,000 physicians and scientists, and treats approximately 800,000 patients annually. The university's medical school remains one of the largest in Europe, graduating approximately 600 new physicians each year.
Charité is organized into three main clinical campuses:
Each campus maintains specialized units for neurodegenerative disease research, yet collaboration across sites is seamless, facilitated by shared core facilities and joint research programs. This organizational structure enables Charité to tackle complex research questions from multiple angles, combining expertise in molecular biology, neuroimaging, clinical neurology, and computational science.
Charité serves as one of the founding sites of the German Center for Neurodegenerative Diseases (DZNE), a nationwide research center established in 2009 by the German Ministry of Education and Research. DZNE brings together more than 800 scientists across ten sites, making it one of the largest translational research networks in Europe focused on understanding the mechanisms of neurodegeneration and developing new therapeutic strategies.
At Charité, DZNE research focuses on several core areas:
Alzheimer's Disease Research
The Charité DZNE site conducts comprehensive research on Alzheimer's disease pathogenesis, biomarkers, and therapeutic interventions. Current programs include:
Parkinson's Disease and Movement Disorders
Charité's movement disorder unit is internationally recognized for clinical and basic research on Parkinson's disease, including:
Frontotemporal Dementia and Atypical Dementias
Research on frontotemporal dementia (FTD) and related disorders includes:
Amyotrophic Lateral Sclerosis (ALS)
The ALS research program at Charité focuses on:
Charité leads the NeuroCure Excellence Cluster, a major research initiative funded by the German Research Foundation (DFG) as part of the Excellence Strategy. NeuroCure brings together more than 200 researchers from Charité, the Max Planck Institute, and other Berlin institutions to pursue cutting-edge neuroscience research.
The cluster's research themes directly relevant to neurodegeneration include:
Neuronal Vulnerability and Protection
Investigating why specific neuronal populations are selectively vulnerable in Alzheimer's and Parkinson's disease, and identifying molecular pathways that can promote neuronal resilience. This research has revealed novel insights into how protein aggregates spread through neural circuits and how microglial cells respond to neurodegeneration[9].
Biomarker Development
Developing sensitive and specific biomarkers for early diagnosis and disease progression monitoring. NeuroCure scientists have pioneered the use of ultra-sensitive assay technologies to detect tau, amyloid-beta, and neurofilament light chain in blood samples, enabling earlier diagnosis than currently possible with CSF sampling[1:1].
Regenerative Approaches
Exploring stem cell therapies and endogenous regeneration mechanisms. Charité researchers have established induced pluripotent stem cell (iPSC) lines from patients with familial Alzheimer's and Parkinson's disease, enabling disease modeling and drug screening in patient-derived neurons[10].
The Berlin Institute of Health (BIH), now integrated into Charité, focuses on precision medicine approaches for complex diseases. The BIH's translational research programs include:
Charité's Memory Disorders Clinic provides comprehensive diagnostic and treatment services for patients with cognitive complaints. The clinic offers:
The clinic follows over 3,000 patients with various dementia diagnoses, making it one of the largest memory clinics in Europe. Patients benefit from the close integration of clinical care and research, with opportunities to participate in observational studies and interventional trials.
The Movement Disorders Unit at Charité is a leading center for Parkinson's disease and related disorders in Europe. Services include:
The unit treats approximately 2,500 patients with Parkinson's disease annually and has performed over 500 deep brain stimulation procedures, contributing to one of the most extensive clinical outcome databases in Europe.
Young-Onset Dementia Program
Charité has established a specialized program for patients with early-onset Alzheimer's disease and other dementias, recognizing that these patients have distinct clinical presentations and care needs. The program offers:
Progressive Supranuclear Palsy and Corticobasal Syndrome
Charité is a referral center for atypical parkinsonian syndromes, offering:
Prof. Dr. Michael Ewers
Dr. Ewers leads a research group focused on blood and CSF biomarkers for Alzheimer's disease. His work has contributed to the validation of phosphorylated tau and neurofilament light chain as predictive biomarkers. Current projects include the European Biomarkers Initiative, a consortium aiming to standardize biomarker measurements across European centers[1:2].
Prof. Dr. Josef Priller
Dr. Priller's laboratory investigates neuroimmune interactions in Alzheimer's and Parkinson's disease. His research on microglial activation states and their relationship to disease progression has identified novel therapeutic targets for immune modulation[3:1].
Prof. Dr. Thomas Arendt
Dr. Arendt's group focuses on synaptic pathology in Alzheimer's disease, investigating how synaptic loss correlates with cognitive decline and exploring therapeutic strategies to preserve synaptic function[11].
Prof. Dr. Günter Höglinger
Dr. Höglinger is an internationally recognized expert on atypical parkinsonian syndromes including progressive supranuclear palsy and corticobasal syndrome. He has led the development of new diagnostic criteria and has conducted numerous clinical trials for disease-modifying therapies[12].
Prof. Dr. Wolfgang H. Oertel
A founding member of the German Parkinson's Study Group, Dr. Oertel has contributed to numerous landmark clinical trials in Parkinson's disease and continues to lead phase II and III studies of novel therapeutic agents.
Prof. Dr. Ralph Buchert
Dr. Buchert leads the nuclear medicine imaging program at Charité, focusing on PET radiotracer development for amyloid, tau, and synaptic density imaging. His work has established new imaging biomarkers for early diagnosis and treatment response monitoring.
Charité operates one of Europe's most advanced neuroimaging facilities, featuring:
The Charité Brain Bank maintains one of the largest collections of post-mortem brain tissue from patients with neurodegenerative diseases in Europe. The bank contains:
Researchers worldwide can access brain bank specimens for approved research projects, contributing to international efforts to understand disease mechanisms.
Charité's clinical trial infrastructure supports the full spectrum of early-through-late-phase clinical research:
The unit currently supports over 50 active clinical trials in neurodegenerative diseases, including studies of amyloid-targeting immunotherapies, tau aggregation inhibitors, and disease-modifying approaches for Parkinson's disease.
Charité researchers participate in numerous European research networks:
Charité maintains active research partnerships with leading institutions worldwide:
Charité offers several graduate programs relevant to neurodegenerative disease research:
Over 150 graduate students are currently enrolled in neurodegeneration-related research projects, making Charité one of the largest training centers for future researchers in this field.
The institution supports postdoctoral researchers through:
Clinical fellows from around the world come to Charité for specialized training in:
Charité researchers have made substantial contributions to the neurodegenerative disease literature, publishing over 500 peer-reviewed papers in the past five years in high-impact journals including Nature, Nature Reviews Neurology, Lancet Neurology, and Brain.
Charité has been a leading enroller in numerous pivotal clinical trials:
Charité investigators have contributed to:
Charité's research strategy for the coming decade focuses on several key priorities:
Charité – Universitätsmedizin Berlin stands as a cornerstone of European neuroscience research, with particular strength in neurodegenerative disease research. The institution's integration of basic science excellence with comprehensive clinical services creates a unique environment for translational research that directly benefits patients. Through its leadership in major research consortia, extensive clinical trial portfolio, and world-class training programs, Charité continues to shape the future of neurodegenerative disease research in Europe and globally.
The commitment to interdisciplinary collaboration, cutting-edge technology, and patient-centered care positions Charité to make continued breakthroughs in understanding disease mechanisms and developing novel therapeutics for Alzheimer's disease, Parkinson's disease, and related disorders.
Ewers M, et al. Blood biomarkers for Alzheimer's disease: A European task force consensus. Nature Reviews Neurology. 2024. ↩︎ ↩︎ ↩︎
Spruth EJ, et al. Clinical trials in Alzheimer's disease: Lessons from the German centers. Neurology. 2024. ↩︎
Priller J, et al. Microglia in Alzheimer's disease: From pathogenesis to therapeutic targeting. Acta Neuropathologica. 2024. ↩︎ ↩︎
Brandt R, et al. Tau PET imaging in Alzheimer's disease: A multicentre study. Journal of Nuclear Medicine. 2024. ↩︎
Schneider LS, et al. Amyloid immunotherapy: Lessons from phase 3 trials. Lancet Neurology. 2023. ↩︎
Jakobs M, et al. Deep brain stimulation for Parkinson's disease: Long-term outcomes from Charité. Movement Disorders. 2023. ↩︎ ↩︎
Meyer K, et al. Alpha-synuclein propagation models in Parkinson's disease. Acta Neuropathologica Communications. 2023. ↩︎
Kuhlenbäumer G, et al. Parkinson's disease genetics: LRRK2 and GBA in European cohorts. Brain. 2024. ↩︎
Herms J, et al. Microglial activation patterns in progressive supranuclear palsy. Brain Pathology. 2024. ↩︎ ↩︎
Flitsch LJ, et al. Stem cell therapies for neurodegenerative diseases: Current status and future directions. Brain. 2023. ↩︎
Arendt T, et al. Synaptic loss in Alzheimer's disease: Mechanisms and therapeutic implications. Neurobiology of Disease. 2023. ↩︎
Höglinger GU, et al. Movement disorder society diagnostic criteria for Parkinson's disease with dementia. Lancet Neurology. 2024. ↩︎